NCT05673512View on ClinicalTrials.gov

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

May 12, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2026

Conditions
HER2 Gene Mutation
Interventions
COMBINATION_PRODUCT

Injection of IAH0968 + CAPEOX

PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient

COMBINATION_PRODUCT

PLACEBO+CAPEOX

PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient

Trial Locations (1)

Unknown

RECRUITING

The First Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

SUNHO（China）BioPharmaceutical CO., Ltd.

INDUSTRY